Recent News

• 01.20.2026 - MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
• 12.24.2025 - MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings
• 12.16.2025 - MAIA Biotechnology Announces $1.51 Million Private Placement
• 12.11.2025 - MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
• 12.11.2025 - MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer

Recent Filings

• 01.13.2026 - EX-99.1 EX-99.1
• 01.13.2026 - 8-K Current report
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - D Notice of Exempt Offering of Securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities